相关实验视频
Updated: Feb 28, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.6K
综合免疫和分子选识别了冠状腺肉瘤中预后子组和治疗点
Agnieszka E Zając1, Piotr Rutkowski1, Anna Szumera-Ciećkiewicz2,3
1Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
International journal of molecular sciences
|February 27, 2026
概括
这项研究开发了冠状腺癌 (ChS) 的免疫突变分类,确定了关键的预后因素,如瘤大小和IDH1突变. 这种分类可能会指导未来的免疫疗法和针对性治疗先进的冠状性硬化症患者.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 软骨肉瘤 (ChS) 是一种罕见的,异质的骨癌,其分子和免疫学基础尚不清楚.
- 目前,没有有效的全身治疗方法存在于晚期ChS患者.
研究的目的:
- 为创建一个免疫突变分类ChS.
- 为了确定新的预后因素和分子标,用于CHS治疗.
主要方法:
- 99名原发性冠状病患者 (G1-G3和非分化) 的免疫分子分析.
- 通过IHC评估了20个免疫反应标志物,并对409个基因进行了针对性的下一代测序.
- 相关的免疫和突变特征与使用多变量Cox模型的整体存活率.
主要成果:
- 确定了三种免疫类型:"冷" (IMP1),"热" (IMP2) 和"中间" (IMP3). 在G1中IMP1是常见的,在非分化的ChS中IMP2是常见的.
- IDH1 / 2 或 TP53 突变与高等级的 ChS 有关.
- IMP2瘤显示出更多的免疫透物;IDH1突变在IMP2病例中很常见.
- 瘤大小,非分化的亚型,IDH1突变和IMP2是独立的负预后因素.
结论:
- 提出了一种针对ChS的免疫突变分类系统.
- 这种系统可以帮助在未来的临床试验中确定适合免疫疗法与IDH突变抑制剂结合的患者.
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:07Tumor Progression
7.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K